Interleukin-12 is detectable in sera of patients with multiple sclerosis - association with chronic progressive disease course?

European Journal of Neurology

Volumn 6, Issue 5, 1999, Pages 591-596

  Heesen, Christoph ^a   Sieverding, Frank ^a   Schoser, Benedikt Gustav Heinrich ^a   Hadji, Bijan ^a   Kunze, Klaus ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Cytokines; Disease course; Immunopathogenesis; Interleukin 12; Interleukin 12 p40 and p70 proteins; Multiple sclerosis

Indexed keywords

INTERLEUKIN 12; PROTEIN P40;

ARTICLE; AUTOIMMUNE DISEASE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TH1 CELL;

EID: 0033401730     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1999.650591.x     Document Type: Article

References (22)

1. Arnason B, Biliau A, Brosnan CF, Burger D, Hartung HP, Hohlfeld R, et al. (1995). Cytokine networks in multiple sclerosis. Neurology 45(suppl):S2-S55.
2. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL (1997). Increased interleukin-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 94:599-603.
3. Coreale J, McMillan M, Li S, McCarthy K, Le T, Weiner LP (1997). Antigen presentation by autoreactive proteolipoprotein-peptide-specific T-Cell clones from chronic-progressive MS patients: role of co-stimulatory B7 molecules and IL-12. J Exp Med 72:27-43.
4. Drulovic J, Mostavica-Stojkoviv M, Levic Z, Stojsavljevis N, Pravica V, Mesaros S (1997). Interleukin-12 and tumor necrosis factor alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 147:145-150.
5. Fassbender K, Ragoschke S, Rossol S, Schwartz A, Mielke O, Paulig A, Hennerici M (1998). Increased release of interleukin-12p40 in MS - association with intracerebral inflammation. Neurology 51:753-758.
6. Germann T, Rüde E (1995). Interleukin-12. Int Arch Allergy Immunopathol 108:103-l12.
7. Giovannoni G, Hartung HP (1996). The immunopathogenesis of multiple sclerosis and Guillain Barré syndrome. Curr Opin Neurol 9:165-177.
8. Issazadeh S, Ljungdahl A, Hojeberg B, Mustafa M, Olsson T (1995). Cytokine production in the cerebrospinal fluid of Lewis rats with experimental allergic encephalomyelitis: dynamics of mRNA expression for interleukin-10, inter-leukin-12, cytolysin and tumor necrosis factor alpha and beta. J Neuroimmunol 61:205-212.
9. Kato K, Shimozato O, Hoshoi K, Wakimoto H, Hamada H, Yagita H, Okumura K (1996). Local production of the p40 subunit of interleukin-12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc Natl Acad Sci USA 93:9085-9089.
10. Kurtzke JM (1983). Rating neurological impairment in multiple sclerosis: an expanded disability status scale. Neurology 33:1444-1452.
11. Leonard JP, Waldburger KE, Goldman SJ (1995). Prevention of experimental autoimmune encephalitis by antibodies against interleukin-12. J Exp Med 181:381-386.
12. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hohlfeld K, et al. (1995). Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154:116-127.
13. Link H, Matusevicius D, Navikas V (1997). Cytokines IL-12, lymphotoxin-alpha, IL-6, perforin and IL-10 in multiple sclerosis. In: Frontiers in multiple sclerosis. Abramsky O, Ovadi H (editors). London: M. Dunitz Ltd. pp. 139-147.
14. Liu J, Marine MW, Wong G, Grail D, Duinn A, Bettadapura J, et al. (1998). TNF is a potent anti-inflammatory cytokine in autoimmune mediated demyclination. Nat Med 4:78-83.
15. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis (1996). Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907-911.
16. Panitch HS, Haley AS, Hirsch RL (1987). Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893-895.
17. Poser, CM, Paty DW, Scheinberg L (1983). New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.
18. Rovaris M, Barnes D, Woodrofe N, du Boulay GH, Thorpe JW, Thompson AJ, et al. (1996). Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J Neurol 243:536-542.
19. Singh VK (1996). Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 66:143-145.
20. Torre D, Ferrario G, Bonetta G, Giola M, Speranza F, Fiori GP (1995). Serum levels of interleukin-12 in adult and paediatric patients with HIV-I infection. AIDS 9:405-406.
21. Trembleau S, Germann T, Gately MK, Adorini L (1995). The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16:383-386.
22. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, Hafler DA (1995). Expression of costimulatory molecules B7-1 (CD 80), B7-2 (CD86), and interleukin-12 cytokine in multiple sclerosis lesions. J Exp Med 182:1985-1996.